Monoclonal gammopathy of undetermined significance,multiple myeloma,and osteoporosis |
| |
Authors: | Béatrice Bouvard Mathieu Royer Daniel Chappard Maurice Audran Emmanuel Hoppé Erick Legrand |
| |
Affiliation: | 1. Department of Medicine, Institute of Clinical Medicine, University of Eastern Finland and Department of Medicine, Kuopio University Hospital, Kuopio, Finland;2. EBMT Lymphoma Working Party, Barcelona, Spain;3. Department of Hematology, Hopital de Purpan, CHU, Toulouse, France;4. Department of Hematology, University College London Hospital, London, UK;5. Department of Hematology, Hopital Haut-Leveque, CHU Bordeaux, Pessac, France;6. Department of Hematology, Hopital Necker, Paris, France;7. Department of Hematology, Cliniques Universitaires St Luc, Brussels, Belgium;8. Department of Hematology, Centre Leon Bernard, Lyon, France;9. Department of Hematology, Addenbrookes Hospital, Cambridge, UK;10. Department of Hematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands;11. EBMT Data Office, Faculté de Médecine Saint-Antoine, Paris, France;12. Department of Hematology, Centre Henri Becquerel, Rouen, France;13. Department of Hematology, Hotel Dieu, Paris, France;14. Department of Hematology, Hague Hospital, The Hague, The Netherlands;15. Department of Medicine V, University of Heidelberg, Heidelberg, Germany;16. Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain |
| |
Abstract: | The finding of monoclonal gammopathy of undetermined significance (MGUS) is not infrequent during an evaluation for osteoporosis or a fracture. In most cases, the diagnosis is MGUS, whose prevalence increases with age. Although the impact of MGUS on bone mineral density, bone remodeling, and the fracture risk remains unclear, this asymptomatic hematological disorder may constitute a risk factor for osteoporosis. Furthermore, each year, 1% of patients with MGUS progress to multiple myeloma, a disease whose pathophysiology and association with bone loss and pathological fractures are increasingly well understood. Osteoporotic fractures, although probably common in myeloma patients, are less likely to be recognized. Here, we discuss the pathophysiology of myeloma and MGUS and their impact in terms of bone mineral density, osteoporotic fractures, and bone turnover markers. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|